Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose naltrexone in lichen planopilaris and frontal fibrosing alopecia
NCT04409041Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of naltrexone in lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA), sponsored by Washington University School of Medicine. Primary endpoints: Change in Patient-Reported Itch at 12 months, Change in Investigator Rated Erythema at 12 months and 1 more. Started Sep 2019; status: completed.
02
Drugs
naltrexone
03
Conditions
lichen planopilaris (LPP)frontal fibrosing alopecia (FFA)
Beyond the preview
Go deeper on NCT04409041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04409041.